European Pharmaceutical Review: Compulsory licenses in Germany

No items found.
​
11 March 2019
Tags
Litigation
Life
Table of contents
  • Toc Heading
  • Toc Heading

Head of EIP’s Düsseldorf office, Christof Höhne, outlines the implications of Germany’s compulsory licensing in an article for the latest issue of the European Pharmaceutical Review. Two recent, high-profile pharmaceutical cases which have set the course for the future of German IP law are analysed by Christof, who highlights the advantages and disadvantages faced by both parties in a licensing negotiation.

The article can be read on the European Pharmaceutical Review website here.

Related articles

See all articles

EIP recognised across the board in IAM Patent 1000, 2026
29 May 2026
We're pleased to be featured again in the IAM Patent 1000, 2026. The guide is one of the most trusted independent rankings of patent professionals worldwide, built on months of research and direct feedback from clients and peers.
​
Five EIP leaders recognised in WIPR 2026
11 May 2026
We are delighted to announce that five members of our team have been named in WIPR Leaders 2026: Jerome Spaargaren, Heather McCann, Gary Moss, Andrew Sharples, and Sebastian Fuchs.
​
EIP recognsied for strategic leadership in patent law at the Professional Services Management Excellence Awards
26 March 2026
EIP has been recognised with two Professional Services Management Excellence Awards 2026, including Excellence in Strategic Leadership and Best in Theme: Leadership. The awards reflect the firm’s commitment to aligning patent expertise with commercial insight, strengthening leadership across the firm and delivering patent strategy that supports investment, growth and high‑value business decisions.
​